-
8
Jun
Partnering with leading rehabilitation centers in Boston, Chicago and Providence, Cyberkinetics is currently recruiting patients to enroll in a pilot clinical trial of the BrainGate⢠Neural Interface System.
The BrainGate⢠System is designed to provide a means for people with severe motor impairment a new method to communicate with a computer directly with their thoughts. As an investigational device, the BrainGate⢠System is only offered through the clinical trial and is not commercially available.
The BrainGate⢠Neural Interface System is currently the subject of a pilot clinical trial being conducted under an Investigational Device Exemption (IDE) from the FDA. The system is designed to restore functionality for a limited, immobile group of severely motor-impaired individuals. It is expected that people using the BrainGate⢠System will employ a personal computer as the gateway to a range of self-directed activities. These activities may extend beyond typical computer functions (e.g., communication) to include the control of objects in the environment such as a telephone, a television and lights.
The BrainGate⢠System is based on Cyberkinetics’ platform technology to sense, transmit, analyze and apply the language of neurons. The System consists of a sensor that is implanted on the motor cortex of the brain and a device that analyzes brain signals. The principle of operation behind the BrainGate⢠System is that with intact brain function, brain signals are generated even though they are not sent to the arms, hands and legs. The signals are interpreted and translated into cursor movements, offering the user an alternate “BrainGate⢠pathway” to control a computer with thought, just as individuals who have the ability to move their hands use a mouse.
Access the BrainGate⢠Here
- Published by Dimitrios A. Adamos in: Stories
- RSS feed subscription!
Neurobot via RSS
